Skip to main content
. Author manuscript; available in PMC: 2023 Jul 1.
Published in final edited form as: Cancer Lett. 2022 Oct 27;552:215981. doi: 10.1016/j.canlet.2022.215981

Figure 5: CNX-774 shows drug interactions across a panel of cytotoxic nucleoside analog drugs identical to that of ENT1 inhibitor NBMPR.

Figure 5:

A) Schematic illustrating nucleoside salvage pathway with candidate CNX-774 targets highlighted. B-H) Dose-response of indicated cytotoxic nucleoside analog drugs in the presence (red line) or absence (black line) of CNX-774 (B-D) or ENT1 inhibitor NBMPR (F-H) along with cartoon showing activation pathway for each nucleoside analog drug. Data represent mean +/− SEM of three biological replicates. E) Relative mRNA expression for indicated genes in S2–013 cells assessed by real time quantitative PCR after 72 hour treatment with BQ (10μM) or vehicle. Data represent mean +/− SD of four replicates. N.D. stands for not detected. I) Table of drug interactions of CNX-774 and NBMPR across a panel of nucleoside analog drugs. Red indicates antagonism, blue indicates cooperativity, black indicates no interaction. Dose response experiments for other drugs in table shown in Figure S5.